ENOV vs. SNN, MSA, ESTA, CDRE, AVNS, ZJYL, SMTI, INGN, LAKE, and CLGN
Should you be buying Enovis stock or one of its competitors? The main competitors of Enovis include Smith & Nephew (SNN), MSA Safety (MSA), Establishment Labs (ESTA), Cadre (CDRE), Avanos Medical (AVNS), Jin Medical International (ZJYL), Sanara MedTech (SMTI), Inogen (INGN), Lakeland Industries (LAKE), and CollPlant Biotechnologies (CLGN). These companies are all part of the "surgical appliances & supplies" industry.
Smith & Nephew (NYSE:SNN) and Enovis (NYSE:ENOV) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, risk, profitability, analyst recommendations, community ranking, earnings and institutional ownership.
25.6% of Smith & Nephew shares are owned by institutional investors. Comparatively, 98.5% of Enovis shares are owned by institutional investors. 1.0% of Smith & Nephew shares are owned by insiders. Comparatively, 2.4% of Enovis shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
In the previous week, Smith & Nephew had 3 more articles in the media than Enovis. MarketBeat recorded 6 mentions for Smith & Nephew and 3 mentions for Enovis. Smith & Nephew's average media sentiment score of 1.26 beat Enovis' score of 1.16 indicating that Enovis is being referred to more favorably in the news media.
Smith & Nephew has higher revenue and earnings than Enovis.
Enovis has a consensus price target of $75.43, suggesting a potential upside of 57.80%. Given Smith & Nephew's stronger consensus rating and higher probable upside, analysts plainly believe Enovis is more favorable than Smith & Nephew.
Smith & Nephew has a beta of 0.8, indicating that its share price is 20% less volatile than the S&P 500. Comparatively, Enovis has a beta of 1.94, indicating that its share price is 94% more volatile than the S&P 500.
Smith & Nephew received 421 more outperform votes than Enovis when rated by MarketBeat users. However, 60.00% of users gave Enovis an outperform vote while only 54.40% of users gave Smith & Nephew an outperform vote.
Smith & Nephew has a net margin of 0.00% compared to Smith & Nephew's net margin of -4.51%. Smith & Nephew's return on equity of 3.98% beat Enovis' return on equity.
Summary
Enovis beats Smith & Nephew on 10 of the 16 factors compared between the two stocks.
Get Enovis News Delivered to You Automatically
Sign up to receive the latest news and ratings for ENOV and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ENOV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
